No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Sanja Selak?

Dr. Sanja Selak

Chief Executive Officer and Scientific Affairs

Origimm Biotechnology GmbH

Direct Phone: +43 *** *******       

Email: s***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Company Description

Welcome to the art of antigen discovery. Reduce risks and costs by partnering with us! A better way to select highly protective antigens ... more

Find other employees at this company (7)

Background Information

Employment History

Head of the Department of Serology and Immune Assays

Intercell AG


Postdoctoral Fellow
Instituto Cajal, CSIC


PhD degree


Web References (9 Total References)

Team | Origimm Biotechnology [cached]

Sanja Selak, PhD

Sanja Selak, PhD
Sanja Selak, PhD
Founder and CEO
After more than 20 years of experience in immunology, serology, and antigen discovery, Sanja now strives to advance vaccine discovery and immune therapy development. Previously she was Head of Department of Serology and Immune Assays at Intercell AG, where she distinguished herself for accurately predicting the success of various vaccine candidates in clinical trials based on sophisticated methods for antigen validation that she designed and developed.
Before moving to industry, Sanja studied and worked at world renowned academic institutes around the globe including the Faculty of Medicine, University of Calgary, Canada, Marine Biological Laboratory (MBL), Woods Hole, MA, USA, the Neurobiology Institute Ramon y Cajal in Madrid, and Neuroscience Institute in Alicante, Spain. She is the author of numerous publications and inventor of several patented products.
For Sanja, science is the highest form of art accomplished by a creative imagination. This approach stems from her music background: Sanja is also a music composer and an accomplished pianist. She especially enjoys playing the colorful and texture-rich pieces of Chopin, Beethoven, Brahms, and Rachmaninoff.

Educating consumers is very important ... [cached]

Educating consumers is very important with vaccines because misconception can spread easily, Origimm Biotechnology Chief Executive Officer Sanja Selak.

There are two basic components in most vaccines: protein from bacteria/virus the vaccine is being used for (antigen) and an adjuvant, which features additional peptides, that trigger an immune response, Selak explained. If you compare the genetic sequence of these peptides to samples in a DNA library, there could be a chance these peptides would have some resemblance to porcine DNA, but this doesn't mean there is porcine in the vaccine, she said.
If there was a line in the sand, a similarity of 85% and above with animal genes should be considered as an animal ingredient, she said.

One Nucleus: Origimm e.U. [cached]

Origimm was founded by Dr. Sanja Selak, the former Head of the Department of Serology and Immune Assays at Intercell in 2012.

Customer Research Case Studies | ProImmune [cached]

Sanja Selak, Intercell AG

Developing Effective Vaccine Strategies at Intercell | ProImmune [cached]

Dr. Sanja Selak (front row, second from left) and the Serology and Immune Assays team at Intercell AG, Austria.

Epitope discovery systems, such as ProImmune's Antigen Characterization Platform, often identify a large number of candidate epitope sequences. While many protein sequences can potentially be antigenic only a few will be relevant as key antigens with addressable immune responses in vivo. To complicate matters further, the available antigens from pathogens may alter over the course of an infection, as Dr. Sanja Selak of Intercell AG, Austria, outlined in her presentation at ProImmune's Antigen Characterization and Biomarker Discovery Summit in January 2011.
Dr. Selak is investigating the B cell epitopes of pathogenic bacteria, and their potential for use in vaccination strategies. Bacterial antigens are especially tricky to work with because bacteria do not express the same proteome consistently. They react to their environment, in particular the availability of micronutrients, and respond by expressing the cellular machinery they require to survive, so that a whole gamut of new antigens can suddenly become available. She has to consider not only the 'who' of candidate epitopes from her discovery strategies, but the 'when' 'where' and 'why', as bacteria adapt to survive in their local habitat.
Since animal models are of limited value with such well-adapted human pathogens, Dr. Selak and her colleagues are now beginning to consider the potential offered by tissue explant cultures for simulation of bacterial microenvironment during infection.
Watch and listen to a slidecast of Sanja Selak's presentation at the ProImmune Antigen Characterization and Biomarker Discovery Summit

Similar Profiles

Other People with this Name

Other people with the name Selak

Tony Selak
Ace Body Corporate Management Pty Ltd

Bill Selak
Hillbrook School

Wendi Selak
Alliant Insurance Services Inc

Chris Selak
Lionsgate incorporated

Boda Selak
Kelt Exploration Ltd.

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory